Conditions Medications Procedures Anatomy Research
Short-Acting Beta-2 Agonist (SABA) Bronchodilator — Modified Release ⚠ Lunar Critical

Combination Salbutamol (Albuterol)

Mechanism of Action

Selectively stimulates beta-2 adrenergic receptors in bronchial smooth muscle, causing bronchodilation.

Indications

Combination formulation. Acute bronchospasm, asthma, COPD exacerbation, exercise-induced bronchospasm. Also useful for regolith dust bronchospasm in exposed workers.

Dosing

Standard (Earth)

See Combination prescribing information. Inhaler: 1-2 puffs (100-200 mcg) every 4-6h. Nebulization: 2.5-5 mg in 3 mL NS every 4-8h.

Lunar Protocol

Metered-dose inhaler function in 1/6g requires special consideration — propellant delivery may be altered. Nebulizer is preferred in lunar medical bay context. Inhaler spacer device recommended for all residents. Regolith-exposed workers: prophylactic use before decontamination shower in severe exposure.

Storage

Standard

Room temperature, protect from heat and direct sunlight.

Lunar (Radiation + Temperature)

Store at 15-25°C. Pressurized MDI canister sensitive to temperature extremes — avoid near habitat wall (temperature variation) or near heating elements. Radiation shielding. 24-month supply. Nebulizer solution more stable than MDI in lunar storage conditions.

Supply Chain & Lunar Pharmacy Notes

WHO Essential Medicine. Very high consumption expected in regolith-exposed workforce. Stock both MDI and nebulizer solution forms. Nebulizer machine requires maintenance — include in medical equipment maintenance schedule.

Drug Interactions

Beta-blockers (antagonism). Diuretics (hypokalemia risk). MAOIs and tricyclics (cardiovascular effects).

Contraindications

Known hypersensitivity. Use with caution in severe cardiac disease.

Side Effects

Tremor, tachycardia, hypokalemia, headache.

Lunar Alternatives

Ipratropium (anticholinergic, good combination with salbutamol), terbutaline (alternative SABA).